JP2012512157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012512157A5 JP2012512157A5 JP2011540796A JP2011540796A JP2012512157A5 JP 2012512157 A5 JP2012512157 A5 JP 2012512157A5 JP 2011540796 A JP2011540796 A JP 2011540796A JP 2011540796 A JP2011540796 A JP 2011540796A JP 2012512157 A5 JP2012512157 A5 JP 2012512157A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- medicament
- class
- selective hdac
- enzastaurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 3
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims 2
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 claims 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 claims 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 claims 1
- KQGPQDMPQIWCMX-UHFFFAOYSA-N 4-pyridin-4-yl-1,3-dihydroimidazole-2-thione Chemical compound N1C(S)=NC(C=2C=CN=CC=2)=C1 KQGPQDMPQIWCMX-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010002156 Depsipeptides Proteins 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- -1 LAQ834 Chemical compound 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- IDQPVOFTURLJPT-UHFFFAOYSA-N N,N'-dihydroxyoctanediamide Chemical compound ONC(=O)CCCCCCC(=O)NO IDQPVOFTURLJPT-UHFFFAOYSA-N 0.000 claims 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 1
- AJRGHIGYPXNABY-UHFFFAOYSA-N N-hydroxy-1-[(4-methoxyphenyl)methyl]-6-indolecarboxamide Chemical compound C1=CC(OC)=CC=C1CN1C2=CC(C(=O)NO)=CC=C2C=C1 AJRGHIGYPXNABY-UHFFFAOYSA-N 0.000 claims 1
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 1
- 229930189037 Trapoxin Natural products 0.000 claims 1
- 229950008805 abexinostat Drugs 0.000 claims 1
- 108010082820 apicidin Proteins 0.000 claims 1
- 229930186608 apicidin Natural products 0.000 claims 1
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
- 229960003094 belinostat Drugs 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 150000001993 dienes Chemical class 0.000 claims 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- MUTBJZVSRNUIHA-UHFFFAOYSA-N n-hydroxy-2-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 MUTBJZVSRNUIHA-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 claims 1
- 229950009215 phenylbutanoic acid Drugs 0.000 claims 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 claims 1
- 108010060597 trapoxin A Proteins 0.000 claims 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 1
- 229960000604 valproic acid Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Claims (4)
- 低レベル又は検出不可能なレベルのHDAC2を有する患者の癌を治療するための医薬を製造するためのエンザスタウリンの使用。
- 患者の癌を治療するための医薬を製造するための、クラスI選択的HDAC阻害剤と併用されるエンザスタウリンの使用であって、前記患者が高レベルのHDAC2を有し、前記医薬がクラスI選択的HDAC阻害剤と併用投与される使用。
- クラスI選択的HDAC阻害剤が、ボリノスタット、デプシペプチド、MS−275、MGCD0103、ベリノスタット、Baceca、パノビノスタット、PCI−24781、TSA、LAQ834、SBHA、酪酸ナトリウム、バルプロ酸、アピシジン、酪酸フェニル、CI994、トラポキシン、SB−429201、ビピリジニウムジエン、SHI−1:2、R306465、SB−379278A、及びPCI−34051からなる群から選択される、請求項2に記載の使用。
- 癌が、結腸直腸癌、胃癌、子宮内膜癌、卵巣癌、乳癌、肝臓癌、肺癌、腎臓癌、皮膚T細胞リンパ腫、膠芽腫、リンパ腫、膵臓癌及び前立腺癌からなる群から選択される、請求項1〜3のいずれか一項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12245108P | 2008-12-15 | 2008-12-15 | |
US61/122,451 | 2008-12-15 | ||
PCT/US2009/066925 WO2010074936A2 (en) | 2008-12-15 | 2009-12-07 | Enzastaurin for the treatment of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012512157A JP2012512157A (ja) | 2012-05-31 |
JP2012512157A5 true JP2012512157A5 (ja) | 2012-08-23 |
Family
ID=41785627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011540796A Withdrawn JP2012512157A (ja) | 2008-12-15 | 2009-12-07 | 癌を治療するためのエンザスタウリン |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110288032A1 (ja) |
EP (1) | EP2376081A2 (ja) |
JP (1) | JP2012512157A (ja) |
KR (1) | KR20110084533A (ja) |
CN (1) | CN102245184A (ja) |
AU (1) | AU2009330492A1 (ja) |
BR (1) | BRPI0922367A2 (ja) |
CA (1) | CA2746085A1 (ja) |
EA (1) | EA201170821A1 (ja) |
MX (1) | MX2011006433A (ja) |
WO (1) | WO2010074936A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA201890869A3 (ru) | 2010-06-03 | 2019-03-29 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) |
WO2013112601A1 (en) * | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
CA2862320A1 (en) * | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Method of treatment of nasopharyngeal cancer |
EP2814493A4 (en) * | 2012-02-17 | 2015-07-22 | Pharmacyclics Inc | COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
AU2014290012B2 (en) * | 2013-07-19 | 2020-01-16 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
WO2017011314A1 (en) * | 2015-07-10 | 2017-01-19 | Paharmacyclics Llc | Btk and hdac combinations |
EP3963092A1 (en) * | 2019-05-02 | 2022-03-09 | Predictive Technology Group, Inc. | Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0817627B1 (en) | 1993-12-23 | 2005-03-09 | Eli Lilly And Company | Protein kinase c inhibitors |
WO2006019851A1 (en) * | 2004-07-23 | 2006-02-23 | Eli Lilly And Company | Methods for diagnosing and treating diabetic microvascular complications |
JP2008545799A (ja) * | 2005-06-10 | 2008-12-18 | ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティー アンド アグリカルチュラル アンド メカニカル カレッジ | 脂肪組織における末梢時計の調節 |
-
2009
- 2009-12-07 WO PCT/US2009/066925 patent/WO2010074936A2/en active Application Filing
- 2009-12-07 JP JP2011540796A patent/JP2012512157A/ja not_active Withdrawn
- 2009-12-07 US US13/130,104 patent/US20110288032A1/en not_active Abandoned
- 2009-12-07 EA EA201170821A patent/EA201170821A1/ru unknown
- 2009-12-07 AU AU2009330492A patent/AU2009330492A1/en not_active Abandoned
- 2009-12-07 CA CA2746085A patent/CA2746085A1/en not_active Abandoned
- 2009-12-07 CN CN2009801503024A patent/CN102245184A/zh active Pending
- 2009-12-07 MX MX2011006433A patent/MX2011006433A/es not_active Application Discontinuation
- 2009-12-07 BR BRPI0922367A patent/BRPI0922367A2/pt not_active IP Right Cessation
- 2009-12-07 EP EP09768467A patent/EP2376081A2/en not_active Withdrawn
- 2009-12-07 KR KR1020117013612A patent/KR20110084533A/ko not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012512157A5 (ja) | ||
NZ599464A (en) | Combination therapies using hdac inhibitors | |
CY1112320T1 (el) | Τιτλοδοτηση της ταπενταδολης | |
EA201300323A1 (ru) | Материалы и способы улучшения функции желудочно-кишечного тракта | |
EA200900155A1 (ru) | Модуляторы фармакокинетических свойств лекарственных средств | |
TW200735859A (en) | Methods of treating cancers with SAHA, carboplatin, and paclitaxel and other combination therapies | |
MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
EA201300242A1 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
DE602007007991D1 (de) | Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
WO2012117257A8 (en) | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer | |
EA201290833A1 (ru) | Применение амисульприда в качестве противорвотного средства | |
WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
BR112015025805A2 (pt) | compostos de ligação de nh3 e métodos para inibir o transporte de fosfato | |
EA201170821A1 (ru) | Энзастаурин для лечения рака | |
CY1117568T1 (el) | Χρηση μιας συνθεσης η οποια περιλαμβανει φορμοτερολη και διπροπιονικη βεκλομεθαζονη για την αγωγη μιας εξαρσης ασθματος | |
ATE543492T1 (de) | Behandlung von lungenkrebs | |
CU20110170A7 (es) | Combinaciones farmacéuticas que comprenden rdea119/bay 869766 para el tratamiento de cánceres específicos | |
MX2010004350A (es) | Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion. | |
EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
UA104274C2 (ru) | Сероводородные производные нестероидных противовоспалительных лекарственных средств | |
TN2010000266A1 (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
MX2009009230A (es) | Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna. |